With Pfizer’s Generic business Upjohn and Mylan Merger planned to complete this November 2020 as an investor you may have some questions in mind, below I have answered couple of the common ones.
Details are gathered by emailing investor relations and using the information on Pfizer and Mylan’s website.
Merger News / Status Updates
Mylan UpJohn Merger has been completed on 16th November 2020. And the stock has now started trading on Nasdaq under the Ticker Symbol: VTRS
As of 18th November its trading at $16.06 a share (-1.71% down on the day) and with a market cap of 8.73 billion.
And on the same day Pfizer is trading at $36.50 a share (+1.29% up on the day) and a market cap of 202.8 billion.
Overall both the stocks haven’t yet had a very significant change in Stock price upon merger since investors had already priced in the merger. VTRS is trading close to where Mylan (MYL) was before the merger and same for PFE
And a new website has been released: viatris.com.
Common Questions –
What will be the name of new company after Mylan and UpJohn Merger ?
Mylan and Pfizer Announced Viatris as the New Company Name.
Logo
Viatris will have a new ticker symbol and the stock will trade on NASDAQ which is where Mylan initially traded.
When will Mylan and Pfizer’s Upjohn merger complete ?
Based on Pfizer’s update on 5th November, combination of the companies is expected to complete by 16th November 2020.
Pfizer has set the close of business on November 13, 2020 as the record date for the spin-off, and the combination of Mylan and the Upjohn Business is expected to close on November 16, 2020.
No action is required by Pfizer common stockholders to receive the distributed shares of Viatris common stock
Can you sell your Viatris Shares while holding on to Pfizer shares ?
During combination period, Pfizer stockholders will have the option of selling the right to receive shares of Viatris common stock while retaining shares of Pfizer common stock. This option to sell will be available on Nasdaq via temporary symbol “VTRSV”.
Can you sell your Pfizer shares during spinoff period and still be able to receive and retain Viatris Stock ?
If you sell your normal Pfizer (PFE) shares during the combination period (12th – 16th nov) that means you are selling both right to receive Viatris shares and the Pfizer to the buyer and you will not receive any Viatris shares after merger is completed.
If as a shareholder you are interested to own Viatris shares but just want to sell Pfizer during combination period you will have option to do so under “PFE WI” on NYSE, you should talk to your broker about this if they support this on their platform.
What if the combination is not completed on time and I have sold my shares ?
Trades under the symbols “VTRSV” and “PFE WI” will settle after the closing date of the combination, which is expected to occur on November 16, 2020. If the combination is not completed, all trades under these temporary symbols will be cancelled.
FYI.
VTRSV is temporary ticker for Viatris and PFE WI is for Pfizer shares that represent the company after spining off Viatris until the merger is completed. After the successful completion of spinoff Pfizer shares will again trade under its same old ticker which is PFE.
Where Viatris stands in Generic Pharma’s business ?
Viatris stands at top in Generic Pharma based on expected sales and market value
Will Pfizer shareholders get Mylan stock ?
Pfizer Shareholders will get Viatris Stock. Ticker symbol not specified yet.
What amount of Viatris Shares will be issued per Pfizer Share ?
For each Pfizer Share you own you will receive 0.12 shares of Viatris.
Or in other words 12 shares per 100 Pfizer Shares.
Calculator to calculate – How many Viatris share you will receive ?
Enter the amount of Pfizer shares you own to know how many Viatris shares you will own.
Example: if you have random number of shares say – 25.55 shares or 8976 shares the calculator will make your life easier.
Management Team
Investor Presentations Summary
Skimming Most Valuable information on the Merger
Merger Summary
New Companies Financial Estimates
Pharmaceutical Competitive Landscape
Peers
New Business Modals Execution Plan
Important Updates
5th Nov 2020 – Pfizer has set the close of business on November 13, 2020 as the record date for the spin-off, and the combination of Mylan and the Upjohn Business is expected to close on November 16, 2020. Full update available here
30th June 2020 – Mylan Shareholders approved proposed merger – 99.6% of Shares Voted in Favor.
18th June 2020 – UpJohn announced Pricing of Senior Notes in Connection with the
Proposed merger. A private offering of $7.45 billion aggregate principal amount of Viatris senior, U.S. dollar-denominated notes and €3.60 billion aggregate principal amount of Upjohn Finance (now subsidiary of Viatris) senior, euro-denominated notes.
Quick Links
Investor Presentations – August 2020
Pfizer and Mylan Announce Two Future Viatris Board Members
About Mylan
Mylan is a global generic pharmaceutical company providing generic healthcare products. Offering a portfolio of over 7,500 marketed products around the world with presense in about 165 countries.
Website: Mylan.com
Investor Relations: investor.mylan.com
About Pfizer Upjohn
With over 130 years of experience, Pfizer Upjohn brings together 20 of the industry’s very recognised brands – products such as Lipitor, Norvasc, Lyrica and Viagra with manufacturing and commercial expertise in more than 120 countries.
Website: pfizer.com/products/upjohn/about
Investor Relations: investors.pfizer.com
